BLOOD PRODUCTS ADVISORY COMMITTEE
September 16-17, 1999
Briefing Information
Agenda
Contents
COMMITTEE UPDATES
Summary of PHS
Advisory Committee Meeting - Stephen Nightingale, MD, OASH, PHS, HHS
Summary of Workshop on
Donor Suitability: Blood Donor Deferral for History of Hepatitis - Robin Biswas, MD, DTTD,
OBRR, CBER, FDA
Summary of Guidance
Document on Revised Precautionary Measures to Reduce the Possible Risk of Transmission of
CJD and nvCJD by Blood and Blood Products - Mary Elizabeth Jacobs, PhD, OBRR, CBER, FDA
Update on Senv Virus -
Edward Tabor, MD, OBRR, CBER, FDA
Update on Status of
Blood Regulations - Martin Ruta, JD, PhD, OBRR, CBER, FDA
HCV Lookback - Paul
Mied, PhD, DTTD, OBRR, CBER, FDA
Post-Donation
Information Affecting Safety of Plasma Derivatives: Revised Algorithm - Edward Tabor, MD,
OBRR, CBER, FDA
I
Strategies for
Increasing the Blood Supply: Informational - Capt. Mary Gustafson, DBA, OBRR, CBER, FDA
II
Nucleic Acid Testing
of Blood Donors for Human Parvovirus B-19 - Thomas Lynch, PhD
III
Antigen/Antibody
Testing for Malaria Informational, Chiang Syin, PhD, DTTD, OBRR, CBER, FDA
IV
Medical Device Panel
Reclassification of HIV Drug Sensitivity Assays -- Andrew Dayton, MD, PhD, Part I
Medical Device Panel
Reclassification of HIV Drug Sensitivity Assays -- Andrew Dayton, MD, PhD, Part II
Haemonetics
Corporation Presentation